Research Use Only

All products sold on this website are intended for research and identification purposes only and are not intended for human dosing, injections, or ingestion. These products are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for legitimate laboratory research and not for human or animal consumption.

What is the CJC-1295 & Ipamorelin blend?

CJC-1295 paired with Ipamorelin has become a subject of interest in scientific research on peptide signaling. CJC-1295 provides extended GHRH activity, while Ipamorelin offers a highly selective ghrelin-mimetic profile. Researchers often investigate this combination to better understand growth hormone dynamics in controlled models.

CJC-1295 Ipamorelin Overview

The CJC-1295 Ipamorelin blend combines two peptides studied for their effects on growth hormone release. CJC-1295, a GHRH analog, is associated with sustained increases in growth hormone and IGF-1, supporting repair and recovery. Ipamorelin, a selective ghrelin receptor agonist, promotes growth hormone release without significantly affecting other hormones. Together, they may provide complementary support for improved body composition, recovery, and anti-aging benefits in clinical research.

Teichman S.L. et al. (2006).

History

The concept of the CJC-1295 Ipamorelin blend stems from parallel developments in peptide research aimed at exploring growth hormone modulation. CJC-1295, a synthetic analog of growth hormone–releasing hormone (GHRH), was developed in the early 2000s to extend the half-life and activity of natural GHRH fragments for research into growth hormone and IGF-1 pathways. Meanwhile, Ipamorelin—a selective ghrelin receptor agonist—emerged from studies in the 1990s investigating ghrelin mimetics and their ability to stimulate growth hormone release with minimal off-target hormonal effects. Together, these peptides became of interest for laboratory research into growth hormone regulation, recovery, and metabolic processes.

Svensson J. et al. (1998).

CJC-1295 Structure

CAS #: 446036-97-1

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

Molecular Weight: 3367.9 g/mol

PubChem ID: 91976842

Ipamorelin Structure

CAS #: 170851-70-4

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

Molecular Weight: 3367.9 g/mol

PubChem ID: 91976842

Research Findings

CJC-1295 and Ipamorelin have been examined in endocrine, metabolic, regenerative, and systemic models, with research exploring their influence on growth hormone pathways, body composition, tissue recovery, and cellular viability. Studies highlight their role in IGF-1 activity, repair processes, and systemic resilience in preclinical settings.

Key Areas of Research:

• Endocrine: Growth hormone, IGF-1, signaling

• Metabolic: Lipids, lean tissue, glucose balance

• Cellular: Proliferation, repair, recovery

• Systemic: Cardiovascular, viability, healing

Together, these findings suggest broad experimental potential for CJC-1295 and Ipamorelin across multiple biological pathways. By modulating growth hormone signaling, influencing metabolic activity, and supporting cellular and systemic recovery, this combination provides a versatile platform for research into regeneration, resilience, and physiological balance in laboratory models.

Teichman S.L. et al., Journal of Clinical Endocrinology & Metabolism, 2006

References

Teichman S.L. et al. (2006). Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab, 91(3):799-805. 

Lapierre S.S. et al. (2006). Sustained GH and IGF-1 responses to CJC-1295 in GHRH knockout mice. Am J Physiol Endocrinol Metab, 291(2):E282-E287.

Svensson J. et al. (1998). Ipamorelin selectively stimulates GH release without affecting cortisol or prolactin. J Clin Endocrinol Metab, 83(9):3094-3101.

Culler M.D. et al. (2002). Pharmacological characterization of ipamorelin, a novel GHRP with GH selectivity. J Endocrinol, 174(2):R1-R6.